The trajectory of Sildenafil presents a intricate picture for shareholders. While the initial release generated massive profits, the expiration of its exclusive rights opened the floodgates to cheaper alternatives, dramatically eroding revenue. This creates a unique dilemma for drug manufacturers banking on similar blockbuster offerings, suggesting

The story of Viagra, and its creator copyright, presents a challenging case study for investors. Originally a blockbuster drug, yielding billions in income, its exclusivity period created a wave of generic competition , significantly diminishing its dominance. While some pharmaceutical companies may try to capitalize on similar conditions , the cur